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Thulium laser transurethral vaporesection of the prostate 
versus transurethral resection of the prostate for men with 
lower urinary tract symptoms or urinary retention 
(UNBLOCS): a randomised controlled trial
Hashim Hashim*, Jo Worthington*, Paul Abrams, Grace Young, Hilary Taylor, Sian M Noble, Sara T Brookes, Nikki Cotterill, Tobias Page, 
K Satchi Swami, J Athene Lane, on behalf of the UNBLOCS Trial Group†
Summary
Background Transurethral resection of the prostate (TURP) is the standard operation for benign prostatic obstruction. 
Thulium laser transurethral vaporesection of the prostate (ThuVARP) is a technique with suggested advantages over 
TURP, including reduced complications and hospital stay. We aimed to investigate TURP versus ThuVARP in men 
with lower urinary tract symptoms or urinary retention secondary to benign prostatic obstruction.
Methods In this randomised, blinded, parallel-group, pragmatic equivalence trial, men in seven UK hospitals with 
bothersome lower urinary tract symptoms or urinary retention secondary to benign prostatic obstruction were 
randomly assigned (1:1) at the point of surgery to receive ThuVARP or TURP. Patients were masked until follow-up 
completion. Centres used their usual TURP procedure (monopolar or bipolar). All trial surgeons underwent training 
on the ThuVARP technique. Co-primary outcomes were maximum urinary flow rate (Qmax) and International 
Prostate Symptom Score (IPSS) at 12-months post-surgery. Equivalence was defined as a difference of 2·5 points 
or less for IPSS and 4 mL per s or less for Qmax. Analysis was done according to the intention-to-treat principle. 
The trial is registered with the ISRCTN Registry, ISRCTN00788389.
Findings Between July 23, 2014, and Dec 30, 2016, 410 men were randomly assigned to ThuVARP or TURP, 205 per 
study group. TURP was superior for Qmax (mean 23·2 mL per s for TURP and 20·2 mL per s for ThuVARP; adjusted 
difference in means –3·12, 95% CI –5·79 to –0·45). Equivalence was shown for IPSS (mean 6·3 for TURP and 
6·4 for ThuVARP; adjusted difference in means 0·28, –0·92 to 1·49). Mean hospital stay was 48 h in both study 
groups. 91 (45%) of 204 patients in the TURP group and 96 (47%) of 203 patients in the ThuVARP group had at least 
one complication.
Interpretation TURP and ThuVARP were equivalent for urinary symptom improvement (IPSS) 12-months post-
surgery, and TURP was superior for Qmax. Anticipated laser benefits for ThuVARP of reduced hospital stay and 
complications were not observed.
Funding UK National Institute for Health Research Health Technology Assessment Programme.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction
Benign prostatic obstruction is a common condition 
resulting from prostate enlargement, and can cause lower 
urinary tract symptoms or urinary retention, with a 
substantial effect on men’s quality of life.1 Surgery to 
relieve the obstruction is indicated after failure of 
medication to improve voiding and to prevent the com­
plications associated with benign prostatic obstruction. 
Bothersome lower urinary tract symptoms secondary to 
benign prostatic obstruction affect around 3% of men 
aged 45–49 years in the UK, increasing to more than 
30% of men aged 85 years and older.2 With an ageing 
population in the UK, the number of patients with benign 
prostatic obstruction is expected to grow, increasing the 
need for surgery.2
Around 25 000 prostate operations are done annually 
in the UK to relieve benign prostatic obstruction. Trans­
urethral resection of the prostate (TURP) has been the 
gold standard of surgery for over 40 years, accounting 
for around 80% of operations. TURP is generally a 
successful procedure but is associated with small but 
significant mortality (0·3% within 30 days) and mor­
bidity risks including transurethral resection syndrome 
(absorp tion of irrigating fluid causing confusion and 
collapse), haemorrhage during the operation, and 
subsequent urinary tract infections.3
Various alternative surgeries, including laser tech­
niques, have been developed over the past 20 years. 
However, uptake has been relatively slow in many parts 
of the world, including the UK, due in part to a long 
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learning curve or inferior clinical outcomes, despite the 
commonly accepted advantages of laser prostatectomy, 
including lower risk of perioperative complications, 
shorter catheterisation time, and reduced hospital stay.3
Although recommended by the UK National Institute 
for Health and Care Excellence (NICE) for several years, 
holmium laser enucleation of the prostate has not 
proved generalisable, requiring extensive experience, 
learning of a unique skill, and the need to morcelate the 
prostate within the bladder to extract the enucleated tis­
sue. Therefore, NICE guidelines suggest performing 
holmium laser enucleation of the prostate at a centre 
specialising in the technique or with mentorship 
ar rangements in place.4 Greenlight laser therapy is also 
approved by NICE but only vaporises the prostate 
without generating tissue for histology, with insufficient 
evidence for use in high­risk patients.5
In this study, we evaluate a laser technique called 
thulium laser transurethral vaporesection of the prostate 
(ThuVARP). ThuVARP uses a thulium­yttrium aluminum 
garnet fibre to deliver light of 2000 nm wavelength to 
vaporise and resect the prostate.6 Unlike other laser 
technologies, ThuVARP uses a surgical technique similar 
to TURP—ie, visual resection of prostatic tissue using a 
working element and resecting in so­called chips, which 
is taught to all urologists during training. The similarity 
in technique to TURP allows a short learning curve for 
surgeons (previously shown in the UNBLOCS trial),7 
giving ThuVARP the potential for widespread adoption 
into clinical practice.
At the time this trial was designed, ThuVARP showed 
positive outcomes in a randomised trial in China, with 
relatively small numbers and short follow­up, but without 
evaluation of all key outcomes.8 European Association of 
Urology guidelines concluded that ThuVARP showed 
equivalent efficacy compared with TURP, but patients 
had shorter catheterisation and hospitalisation times, 
with lower adverse events than for TURP (intraoperative 
and postoperative bleeding; level of evidence 1b).9 
However, 2010 NICE guidelines recommended that laser 
vaporisation or vaporesection techniques should only be 
offered as part of a randomised trial comparing these 
techniques with TURP, because of the restricted evidence 
base.4 In the UNBLOCS trial, we chose ThuVARP for 
Research in context
Evidence before this study
Transurethral resection of the prostate (TURP) is the standard 
operation for men with benign prostatic obstruction. 
This procedure is generally considered to be successful; 
however, it is associated with small but clinically significant 
risks of morbidity and mortality. Thulium laser transurethral 
vaporesection of the prostate (ThuVARP) is a laser procedure 
that vapourises and resects the prostate using a technique 
similar to TURP. The 2013 European Association of Urology 
(EAU) guidelines for the treatment and follow-up of 
non-neurogenic male lower urinary tract symptoms, 
including benign prostatic obstruction, formed the evidence 
base for the UNBLOCS study. The guidelines were based on a 
literature search including all articles published in English in 
PubMed, MEDLINE, Web of Science, and Cochrane databases. 
Based on the one randomised controlled trial and one 
non-randomised prospective controlled trial that had been 
done with small and medium-sized prostates, the EAU 
guidelines stated that ThuVARP showed equivalent efficacy to 
TURP. Moreover, ThuVARP achieved shorter catheterisation 
and hospitalisation times, with a lower level of adverse events 
than TURP (intra-operative and postoperative bleeding; 
level of evidence 1b). The 2010 National Institute for Health 
and Care Excellence (NICE) Clinical Guideline recommended 
that laser vapourisation or vaporesection techniques should 
only be offered as part of a randomised trial comparing 
these techniques with TURP because of the limited evidence 
base.
Added value of this study
To our knowledge, the UNBLOCS trial is the largest randomised 
trial to compare ThuVARP to standard TURP. This masked trial 
included patients with urinary retention, who are frequently 
excluded from benign prostatic obstruction surgery trials, 
and made extensive use of patient-reported outcome 
measures. In contrast to previous studies, the trial showed that 
ThuVARP and TURP procedures achieve equivalent patient-
reported urinary symptoms after surgery (International 
Prostate Symptom Score), but that TURP is superior in the 
urinary flow rate achieved (Qmax). TURP and ThuVARP had 
similar results across almost all other clinical operative 
outcomes, including bleeding and complication rates, length of 
stay in hospital, and patient-reported urinary symptoms, 
sexual symptoms, quality of life, and satisfaction after surgery. 
Patients with urinary retention had similarly positive outcomes 
after benign prostatic obstruction surgery as patients with 
lower urinary tract symptoms, contrary to the commonly held 
urological belief that this population has poorer outcomes.
Implications of all the available evidence
Overall, both ThuVARP and TURP can be recommended as 
clinically effective procedures for relieving benign prostatic 
obstruction; however, TURP achieved a superior urinary flow 
rate. The potential advantages of ThuVARP in reducing blood 
loss and shortening hospital stay were not observed in this 
study. Our results suggest that it is appropriate that new 
treatment alternatives continue to be compared with the 
current standard of TURP, as per the NICE guidelines. Our trial 
results can be used to update the literature and urology 
guidelines, allowing patients to be more informed at the point 
of consent on the risks and benefits of such procedures, 
especially with regard to side-effects.
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comparison against TURP in a pragmatic randomised 
trial because of the potential for improved clinical 
outcomes paired with ease of gener alisability.
Methods
Study design and participants
The UNBLOCS study is a multicentre, pragmatic, ran­
domised, parallel­group equivalence trial of ThuVARP 
versus standard TURP. We aimed to determine whether 
ThuVARP was equivalent to TURP in men with benign 
prostatic obstruction, in terms of the patient­reported 
International Prostate Symptom Score (IPSS) and 
maximum urine flow rate (Qmax). The trial was done in 
four university teaching hospitals and three district 
general hospitals in the UK. Men presenting in secondary 
care with either bothersome lower urinary tract symp­
toms or urinary retention, secondary to benign prostatic 
obstruction, and suitable for TURP surgery (having 
failed conservative and medical therapy), were recruited. 
Men were excluded if they had neuro genic lower urinary 
tract symptoms, prostate cancer, previous prostate or 
urethral surgery, a prostate specific antigen level outside 
the normal age­related range without prostate cancer 
excluded, or were unable to give informed consent or 
complete trial documentation.
Figure 1: Trial profile
ThuVARP=thulium laser transurethral vaporesection of the prostate. TURP=transurethral resection of the prostate. 
Qmax=maximum urinary flow rate. IPSS=International Prostate Symptom Score.
475 men enrolled
410 randomly assigned
2 excluded
1 withdrew
1 died
205 allocated to ThuVARP
152 received ThuVARP
12 received TURP
36 converted to TURP mid-procedure
3 received an alternative treatment
2 withdrew all data
152 completed 6-week IPSS
171 completed 3-month Qmax
158 completed 3-month IPSS
65 not randomly assigned
11 lack of theatre coverage or equipment
10 later found to be ineligible
8 patient did not want or require surgery
8 surgery not appropriate due to risks
8 surgery appointment sooner if outside the trial
7 randomisation failed or missed
4 surgery date outside the trial window
2 patient declined to continue in the study
2 alternative surgery done on the day
1 deceased
4 reason missing
168 completed 12-month Qmax
151 completed 12-month IPSS
1 withdrew
4 withdrew
205 allocated to TURP
200 received TURP
3 urethral stricture
1 tight bladder neck
1 withdrew all data
154 completed 6-week IPSS
176 completed 3-month Qmax
157 completed 3-month IPSS
176 completed 12-month Qmax
159 completed 12-month IPSS
1 withdrew
5 excluded
4 withdrew
1 died
ThuVARP* (n=203) TURP* (n=204)
Age, years 70·85 (7·85) 69·22 (7·91)
Bothersome lower urinary tract 
symptoms
94 (46%) 102 (50%)
Urinary retention 109 (54%) 102 (50%)
Ethnicity†
White 196 (98%) 197 (98%)
Black, African, or Caribbean 1 (<1%) 1 (<1%)
Asian or British Asian 2 (1%) 1 (<1%)
Mixed or multiple ethnicities 0 1 (<1%)
Other 0 1 (<1%)
BMI (on day of surgery)‡, kg/m² 28·54 (4·16) 27·83 (4·32)
Comorbidities at baseline (from the Charlson Comorbidity Index)
None 113 (56%) 115 (56%)
One 57 (28%) 58 (28%)
More than one 33 (16%) 31 (15%)
Catheterisation status (on the day of surgery)
No catheter§ 96 (48%) 97 (48%)
Catheterised 106 (52%) 107 (52%)
Intermittent 4 (4%) 10 (9%)
Indwelling 93 (88%) 92 (86%)
Type not disclosed¶ 9 (8%) 5 (5%)
Urinary measures
Maximum flow rate, Qmax|| 8·90 (5·90) 8·00 (6·00)
Post-void residual, mL|| 157 (53–285) 140 (80–300)
Voided volume, mL|| 186 (110–251) 181 (117–244)
Prostate size, g** 35 (25–50) 40 (20–50)
Patient has had urodynamics†† 37 (19%) 44 (23%)
Data are mean (SD), n (%), or median (IQR). ThuVARP=thulium laser transurethral 
vaporesection of the prostate. TURP=transurethral resection of the prostate. 
BMI=body-mass index. Qmax=maximum urinary flow rate.*Two patients in the 
ThuVARP group and one patient in the TURP group requested for all their data to be 
withdrawn; therefore, the patient totals are 203 and 204, respectively. †Data are 
missing for five patients in the ThuVARP group and three patients in the TURP 
group. ‡Data are missing for ten patients in the ThuVARP group and ten patients in 
the TURP group. §Data are missing for one patient in the ThuVARP group. ¶Treated 
as indwelling for the imputed primary analysis, as these patients were unable to void 
at baseline. ||Urinary measures were excluded for men with indwelling catheters at 
baseline; the minimum numbers who completed baseline urinary measures were 
92 and 99 for ThuVARP and TURP, respectively. **Data were missing on prostate size 
for 17 patients in the ThuVARP group and 23 in the TURP group. ††Data were missing 
on urodynamics for 11 patients in the ThuVARP group and 13 in the TURP group.
Table 1: Baseline sociodemographic and clinical characteristics
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For the study protocol see 
https://www.fundingawards.
nihr.ac.uk/award/12/35/15
Ethics approval was received from the NRES Com­
mittee South Central—Hampshire B Ethics Committee 
(reference 13/SC/0644). The Consolidated Standards of 
Reporting of Trials (CONSORT) guidelines for outcomes 
were followed. All patients provided written informed 
consent and the trial was conducted according to Good 
Clinical Practice guidelines.
The study protocol is available online and has been 
previously published.10
Randomisation and masking
Patients were randomly assigned (1:1) to TURP or 
ThuVARP through an automated, computer­generated 
web or telephone randomisation system. Randomisation 
was done at the point of surgery by the surgeon or 
research nurse, was stratified by centre and presentation 
(bothersome lower urinary tract symptoms or urinary 
retention), and random blocking was used.
Patients remained masked to their allocation until 
completion of follow­up. Randomisation was done after the 
patient was anaesthetised to facilitate patient blinding and 
to conceal allocation until the patient was in surgery. Ward 
staff, theatre notes, and discharge letters were blinded to 
avoid inadvertent unmasking of patients after surgery, with 
additional measures to avoid unmasking during surgery 
in patients undergoing spinal anaesthetic. Participants 
were informed of the type of surgery received after 
completion of their 12­month follow­up. Patient masking 
was assessed by asking patients whether they knew their 
allocation in their 12­month questionnaire. Surgeons doing 
the interventions and outcome assessors were not masked.
Procedures
Given the pragmatic design of the trial, centres used their 
usual TURP procedure (monopolar or bipolar).10 We used 
a LISA Revolix 120W thulium laser system (Katlenburg­
Lindau, Germany) for ThuVARP using a 550 µm fibre.6 
All trial surgeons underwent training on the ThuVARP 
technique for the study and the competence of each 
surgeon was assured by an independent assessor before 
entering patients into the trial.
Patient clinical outcomes were recorded at baseline 
(pre­surgery), pre­operatively, and peri­operatively during 
their hospital stay for their allocated surgery, and at 
3 months and 12 months post­surgery. Qmax, post­void 
residual, and voided volume were measured before 
surgery. Post­void residual and voided volume were 
measured post­operatively, and Qmax, post­void residual, 
and voided volume were measured at 3 months and 
12 months post­surgery. Blood parameters were also 
measured at baseline and postoperatively.
Patient­reported outcomes were collected by paper 
questionnaires completed by participants at the baseline 
clinic visit, by post at 6 weeks, and at their 3­month and 
12­month clinic visits. Patients received a single reminder 
if questionnaires were not returned at 6 weeks and 
3 months, and two reminders at 12 months. Baseline 
questionnaire data and urinary flow measures were 
collected for patients with lower urinary tract symptoms; 
however, equivalent data could not be collected for 
Score range (low 
to high severity)
ThuVARP (n=100) TURP (n=107)
IPSS—urinary symptoms*
IPSS storage subscale 0–15 9·51 (3·07) 10·09 (3·14)
Frequency 0–5 3·63 (1·25) 3·83 (1·42)
Urgency 0–5 2·97 (1·64) 3·30 (1·44)
Nocturia 0–5 2·97 (1·34) 2·83 (1·35)
IPSS voiding subscale 0–20 12·17 (4·55) 12·45 (4·63)
Incomplete emptying 0–5 3·12 (1·72) 3·29 (1·60)
Intermittency 0–5 2·94 (1·61) 2·99 (1·58)
Weak stream 0–5 3·91 (1·36) 3·80 (1·30)
Straining 0–5 2·20 (1·77) 2·37 (1·79)
Total IPSS score 0–35 21·74 (6·37) 22·56 (6·78)
ICIQ-MLUTS—urinary symptoms†
Voiding score 0–20 11·62 (4·35) 11·78 (3·92)
Incontinence score 0–24 5·75 (3·42) 6·10 (3·85)
Daytime frequency (>8 times) NA 42 (52%) 56 (58%)
Nocturia (>1 time per night) NA 75 (82%) 81 (84%)
ICIQ MLUTS—sexual function‡
Reduced or no erections NA 65 (76%) 65 (71%)
Reduced or no ejaculation NA 73 (86%) 75 (84%)
Painful ejaculation NA 13 (18%) 30 (35%)
Urinary symptoms affected sex life NA 56 (68%) 62 (70%)
International Index of Erectile Function—sexual function§
Total score 25–5 14·11 (6·51) 16·49 (6·17)
IPSS—quality of life¶
IPSS quality-of-life score 0–6 4·89 (1·11) 5·01 (1·01)
ICIQ-LUTS quality-of-life module—presence of limitations||
Role limitations NA 73 (83%) 79 (81%)
Physical limitations NA 77 (85%) 84 (87%)
Social limitations NA 57 (64%) 76 (80%)
Personal relationships NA 63 (84%) 67 (81%)
Emotions NA 68 (77%) 84 (89%)
Sleep or energy NA 89 (99%) 91 (86%)
Severity measures NA 78 (90%) 82 (86%)
ICIQ-LUTS quality of life—urinary symptom effect on**
Getting embarrassed NA 59 (66%) 66 (68%)
Overall interference with everyday life 0–10 6·02 (2·87) 6·49 (2·94)
Data are mean (SD) or n (%), unless otherwise indicated. Based on exclusion of total withdrawals and numbers with 
indwelling catheters, the maximum number of potential responders was 100 for ThuVARP and 107 for TURP. 
ThuVARP=thulium laser transurethral vaporesection of the prostate. TURP=transurethral resection of the prostate. 
IPSS=International Prostate Symptom Score. ICIQ-MLUTS=International Consultation on Incontinence Questionnaire 
Male Lower Urinary Tract Symptoms Module. ICIQ-LUTS=International Consultation on Incontinence Questionnaire 
Lower Urinary Tract Symptoms. NA=not applicable. *Minimum numbers analysed were 86 patients for ThuVARP 
and 89 patients for TURP, with larger scores indicating more severe symptoms. †Minimum numbers analysed were 
89 patients for ThuVARP and 96 patients for TURP, with larger scores indicating more severe symptoms. ‡Minimum 
numbers analysed were 72 patients for ThuVARP and 85 patients for TURP. §Numbers analysed were 65 patients for 
ThuVarp and 74 patients for TURP; lower scores indicate more severe erectile dysfunction (5–7=severe, 8–11=moderate, 
12–16=mild to moderate, 17–21=mild, and 22–25=none). ¶Numbers analysed were 90 patients for ThuVARP and 
97 patients for TURP; higher scores indicate poorer quality of life. ||Minimum numbers analysed were 75 patients for 
ThuVARP and 83 patients for TURP. **Minimum numbers analysed were 90 patients for ThuVARP and 95 patients for 
TURP; higher scores indicate poorer quality of life.
Table 2: Baseline patient-reported outcome measures of non-catheterised patients
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catheterised patients with urinary retention because of 
their inability to void.
Sites followed their usual practice for management of 
patients on anticoagulation medication. Prostate size was 
assessed by digital rectal examination.
Outcomes
The co­primary outcomes were maximum urine flow 
rate (Qmax; mL per s) and IPSS score at 12 months 
postsurgery. IPSS is a well­established and validated 
patient­reported outcome, with a score that ranges from 
0 to 35, with higher scores indicating more severe urinary 
symptoms.11 Qmax is a urodynamic clinical measure that 
is used across benign prostatic obstruction trials.
Surgical secondary outcomes comprised complications 
occurring after leaving recovery until completion of 
12­month follow up (Clavien­Dindo classification12) and 
length of hospital stay. Perioperative complications were 
reported separately without Clavien­Dindo classification. 
The additional secondary outcomes of postoperative 
catheterisation time (time to successful trial without 
catheter and ongoing catheter use), urinary post­void 
residual, blood loss during surgery (change in haemo­
globin and blood transfusion rate), and absorption of 
irrigation fluid (change in serum sodium) were added as a 
protocol amendment (approved June 1, 2017).
Lower urinary tract symptoms were measured using the 
IPSS and International Consultation on Incontinence 
Questionnaire Male Lower Urinary Tract Symptoms 
Module (ICIQ­MLUTS).13 Urinary symptoms included 
voiding symptoms (related to passing urine, such as 
hesitancy and poor urinary flow) and storage symptoms 
(related to urine bladder storage, such as frequency 
and nocturia). Sexual function was measured by the 
International Consultation on Incontinence Question­
naire Male Sexual Matters Associated with Lower Urinary 
Tract Symptoms Module (ICIQ­MLUTSsex)14 and the 
International Index of Erectile Function (IIEF).15 Quality 
of life was measured by the IPSS QoL subscore and the 
International Consultation on Incontinence Questionnaire 
Lower Urinary Tract Symptoms Quality of Life Module 
(ICIQ­LUTSqol),16 and patient satisfaction with surgery 
by the ICIQ Satisfaction questionnaire.17 All question­
naires were fully validated, with the exception of the 
partly validated ICIQ Satisfaction questionnaire. Patient­
reported outcomes for participants with an indwelling 
catheter were not included in the analysis at baseline 
(185 of 406 patients) or 12 months after surgery (six of 
387 patients). Resource use and qualitative interview 
secondary outcomes are reported elsewhere.18
Statistical analysis
The sample size calculation assumed that men randomly 
assigned to ThuVARP should have clinical outcomes 
equivalent to those who were randomised to TURP. For 
primary outcomes, differences in IPSS score of no more 
than 2·5 points and no more than 4 ml per sec for Qmax 
were hypothesised as suggesting equivalence. These 
hypo theses were based on the minimally clinically 
important differences in the lit erature and discussions 
with urologists on clinically relevant cutoffs. Further 
details on these justifications can be found in the 
statistical analysis plan.19 Assuming SDs of 9 ml per sec 
for Qmax and 5 units for IPSS, the target sample size for 
patients needed to complete the 12­month follow­up was 
163 per group. This sample size provided 85% power to 
show equivalence for Qmax and just over 90% power for 
IPSS, at a two­sided α of 5%. Assuming 20% loss to 
follow­up, we needed to recruit 410 men.
The main statistical analyses were prespecified using 
a statistical analysis plan.19 As the primary outcomes for 
n (ThuVARP:TURP) ThuVARP, mean (SD) TURP, mean (SD) Crude difference in 
means (95% CI)
Adjusted difference in 
means* (95% CI)
IPSS score 197:199 6·43 (6·79) 6·26 (5·79) 0·16 (–1·08 to 1·41) 0·28 (–0·92 to 1·49)
Qmax 197:199 20·16 (16·88) 23·24 (13·28) –3·08 (–5·75 to –0·41) –3·12 (–5·79 to –0·45)
ThuVARP=thulium laser transurethral vaporesection of the prostate. TURP=transurethral resection of the prostate. IPSS=International Prostate Symptom Score. 
Qmax=maximum urinary flow rate. *Adjusted for centre and baseline diagnosis.
Table 3: 12-month results for primary endpoints after randomisation to ThuVARP or TURP
Figure 2: IPSS and Qmax over time, across baseline diagnosis and randomisation group
(A) Total IPSS score. (B) Qmax level in mL per s. This figure is based on complete cases only, with no imputation for 
missing values, and patients with urinary retention who completed baseline scores have been removed from the analysis 
(n=13 for IPSS and n=21 for Qmax). IPSS=International Prostate Symptom Score. ThuVARP=thulium laser transurethral 
vaporesection of the prostate. TURP=transurethral resection of the prostate. Qmax=maximum urinary flow rate.
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this trial were testing for equivalence between the study 
groups, emphasis was placed on estimates and CIs and 
their distances from the prespecified equivalence 
margins. All analyses were done using intention­to­treat 
randomly allocated groups and, where possible, were 
adjusted for centre and patient diagnosis at baseline 
(lower urinary tract symptoms vs urinary retention).
Complications of treatment were also explored on 
an as­treated basis to identify any treatment­specific 
complications. Binary outcomes were presented as n (%) 
and continuous outcomes as mean (SD) or median (IQR), 
as appropriate. Baseline data were considered imbalanced 
by randomised group if there was more than 0·5 SD or 
an absolute difference of 10%.
In line with the protocol10 and statistical analysis plan,19 
missing data were used in the comparison of IPSS scores 
and Qmax levels for the primary analysis of this trial. 
We used multiple imputation by chained equations 
to impute missing values for the primary outcomes and 
details can be found in the appendix (appendix p 2). 
The primary analyses of Qmax and IPSS were done with 
a linear regression model, adjusting for centre and 
baseline presentation (urinary retention vs lower urinary 
tract symptoms). Various sensitivity analyses were done 
and details of these can be found in the appendix 
(appendix p 2).
For all other secondary analyses, analyses were based 
on complete case analyses and assessing for superiority; 
therefore, estimates, CIs, and p values are presented. We 
explored complications using ordinal logistic regression 
to account for quantity and severity. Where patients had 
multiple complications, and therefore grading within 
one complication type, the highest was taken. Given the 
small number of complications, we did not adjust this 
analysis for centre or baseline diagnosis. We analysed 
additional clinical outcomes using linear, logistic, or 
ordinal logistic regression, as appropriate. We analysed 
time to successful trial without catheter using a Cox 
proportional hazards model. Where continuous out­
comes were skewed, the median and IQR are presented. 
We used linear regression to allow adjustment; however, 
relevant model assumptions were checked along with 
com parisons to a non­parametric approach. Quintiles of 
post­void residual were calculated and analysed using 
ordinal logistic regression because of the high proportion 
of patients with zero post­void residual at 12 months.
Patient­reported outcomes were scored and analysed 
as recommended, including voiding and incontinence 
scores (ICIQ­MLUTS) and an overall erectile dysfunction 
score (IIEF). Dichotomous variables were also created to 
assist reporting20 (appendix p 5).
Each patient­reported outcome was compared between 
study groups at 12 months using linear and logistic 
regression as appropriate. Where the dis tributions of 
continuous variables were skewed, means (and SD) are 
presented to see beyond ceiling effects (eg, the median 
satisfaction score was 10 out of 10 for both groups). The 
adjusted p value from each regression model on skewed 
data was also compared with the one achieved from the 
Mann­Whitney test to ensure consistency. Where ordinal 
outcomes were dichotomised, to aid interpretation 
results were also compared on an ordinal scale to ensure 
consistency. Analyses were not adjusted for baseline 
ThuVARP TURP Odds ratio (95% CI)* p value
Bleeding requiring haemoglobin measure
Not experienced 188 (94%) 189 (95%) 1·00 (0·42–2·35) 0·992
Grade I 10 (5%) 8 (4%) ·· ··
Grade II 0 2 (1%) ·· ··
Grade IIIb 1 (1%) 1 (1%) ·· ··
Transurethral resection syndrome†
Not experienced 203 (100%) 203 (100%) ·· ··
Catheter misplacement
Not experienced 198 (100%) 199 (>99%) ·· ··
Grade II 0 1 (1%) ·· ··
Clot retention
Not experienced 190 (95%) 189 (94%) 0·74 (0·30–1·79) 0·498
Grade I 9 (5%) 9 (4%) ·· ··
Grade II 0 2 (1%) ·· ··
Grade IIIb 0 1 (<1%) ·· ··
Urethral stricture
Not experienced 191 (96%) 195 (98%) 1·43 (0·45–4·59) 0·546
Grade I 0 2 (1%) ·· ··
Grade II 0 0 ·· ··
Grade IIIa 4 (2%) 0 ·· ··
Grade IIIb 3 (2%) 3 (2%) ·· ··
Urinary tract infection
Not experienced 131 (68%) 136 (68%) 1·02 (0·67–1·55) 0·938
Grade I 10 (5%) 11 (6%) ·· ··
Grade II 51 (26%) 53 (27%) ·· ··
Grade IVb 1 (1%) 0 ·· ··
Pyrexia of unknown region
Not experienced 188 (97%) 190 (98%) 1·50 (0·42–5·41) 0·533
Grade I 2 (1%) 0 ·· ··
Grade II 4 (2%) 4 (2%) ·· ··
Sepsis, septicaemia, or abscess
Not experienced 190 (99%) 189 (98%) 0·50 (0·09–2·76) 0·427
Grade II 1 (1%) 3 (2%) ·· ··
Grade Iva 0 1 (1%) ·· ··
Grade IVb 1 (1%) 0 ·· ··
Other infection
Not experienced 186 (97%) 187 (96%) 0·71 (0·22–2·29) 0·570
Grade I 1 (1%) 0 ·· ··
Grade II 4 (2%) 7 (4%) ·· ··
Data are n (%), unless otherwise indicated. Data exclude perioperative complications. When patients had multiple 
events or grades within one complication type, the highest was taken. For each item, patients were not included if data 
were missing on complications in either their postoperative, 3-month, or 12-month clinical report form. Categories of 
Clavien-Dindo grading are missing when they were not experienced by at least one patient. ThuVARP=thulium laser 
transurethral vaporesection of the prostate. TURP=transurethral resection of the prostate. *Ordinal logistic regression 
not adjusted for centre or baseline diagnosis given the small number of events. †Transurethral resection syndrome 
data were not collected at 3 months or 12 months.
Table 4: Postoperative surgical complications (Clavien-Dindo scores per patient)
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measures of the patient­reported outcomes because of 
an inability to collect data from catheterised patients.
We used STATA version 15.1 for all analyses. The trial 
was overseen by an independent data monitoring 
committee and is registered with the ISRCTN Registry, 
ISRCTN00788389.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results 
Between July 23, 2014, and Dec 30, 2016, we randomly 
assigned 410 men, 205 to each study group. Patient 
follow­up was completed in December, 2017. 152 (74%) of 
205 participants allocated to ThuVARP and 200 (98%) 
of 205 participants allocated to TURP underwent their 
randomly assigned procedure (figure 1). Reasons for 
changes in treatment are listed in the appendix (p 5). 
Looking at conversions from ThuVARP to TURP mid­
procedure, if the recruitment period was divided per 
surgeon into two halves, 13 (14%) of 94 procedures 
were converted in the first half and 22 (24%) of 
90 procedures were converted in the second half. Overall, 
16 participants withdrew from the study before their 
12­month primary endpoint (three requested complete 
data withdrawal). At 12 months postsurgery, 310 (76%) of 
410 participants completed the IPSS questionnaire and 
344 (84%) had their Qmax recorded (figure 1).
Participant, clinical and patient­reported characteristics 
in the two trial groups were similar at baseline, with only 
painful ejaculation differing by more than an absolute 
difference of 10% (tables 1, 2). Around half the trial 
population presented with bothersome lower urinary 
tract symptoms and half with urinary retention, consis­
tent with 213 (52%) of 406 patients being catheterised 
at baseline. Baseline urinary flow rates were generally 
poor, in line with the need for benign prostatic obstruc­
tion surgery, with a mean of around 9 mL per s. Patients 
also had a mean baseline IPSS score of 22, indicating 
severe symptoms.
The two procedures were equivalent (margin 2·5) 
for IPSS at 12 months post­surgery, with an adjusted 
difference in means of 0·28 points (95% CI –0·92 to 1·49; 
table 3). ThuVARP had a lower mean Qmax at 12 months 
compared with TURP (adjusted difference in means 
of –3·12, 95% CI –5·79 to –0·45), with the lower CI 
outside the equivalence range (–4 to 4), indicating the 
treat ments are non­equivalent. Changing to superiority 
testing (without statistical penalty after an equivalence 
ana lysis),21 suggested that TURP was superior to 
ThuVARP for Qmax (table 3). Per­protocol and complier 
average causal effect models strengthened the results of 
n (ThuVARP:TURP) ThuVARP TURP Adjusted comparison* 
(95% CI)
p value
Total number of complications during the 
12-month period†
·· ·· ·· 1·10 (0·75 to 1·63) 0·623
0 NA 107 (53%) 113 (55%) ·· ··
1 NA 28 (14%) 27 (13%) ·· ··
>1 NA 68 (34%) 64 (31%) ·· ··
Surgery outcomes
Length of hospital stay, h‡ 198:198 48 (29 to 58) 48 (29 to 61) –3·28 (–9·61 to 3·06) 0·310
Transfusion required, yes vs no§ 200:202 3 (2%) 4 (2%) 0·79 (0·17 to 3·62) 0·765
Postoperative catheter time, days¶ 195:198 2 (1 to 5) 2 (1 to 4) 1·02 (0·83 to 1·26) 0·830
Catheter required at 3 months§ 196:201 5 (3%) 5 (2%) 0·99 (0·28 to 3·49) 0·988
Catheter required at 12 months§ 192:195 4 (2%) 2 (1%) 1·95 (0·35 to 10·82) 0·446
Haemoglobin—blood loss, g/L‡|| 146:138 –6 (–13 to –1) –8 (–16 to –2) 0·88 (–2·14 to 3·89) 0·568
Serum sodium, mmol/L‡|| 141:138 –2 (–4 to –1) –3 (–4 to –1) 0·40 (–0·34 to 1·14) 0·290
Post-void residual at 12 months, mL** ·· ·· ·· 1·46 (1·00 to 2·15) 0·053
Quintile 1 (range 0 to 0) NA 39 (23%) 39 (22%) ·· ··
Quintile 2 (range 2 to 34) NA 21 (12%) 39 (22%) ·· ··
Quintile 3 (range 35 to 71) NA 35 (21%) 35 (20%) ·· ··
Quintile 4 (range 72 to 140) NA 32 (19%) 36 (20%) ·· ··
Quintile 5 (range 141 to 1000) NA 42 (25%) 27 (15%) ·· ··
Data are n (%) or median (IQR), unless otherwise indicated. ThuVARP=thulium laser transurethral vaporesection of the prostate. TURP=transurethral resection of the prostate. 
NA=not applicable. *Adjustment for centre and baseline diagnosis. †Ordinal logistic regression comparing 0, 1, and >1 complications; to ensure all complications were 
captured, patients were included if they had at least one non-missing complication. ‡Linear regression for continuous outcomes. §Logistic regression for binary outcomes, 
not adjusted for centre because of perfect prediction (catheter outcomes refer to indwelling catheters only). ¶Analysed using a Cox proportional hazards model. ||Negative 
values indicate that levels collected postoperatively were lower than those collected at baseline. **Analysed using ordinal logistic regression.
Table 5: Secondary surgical outcomes
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the main intention­to­treat analysis (appendix p 6). For 
Qmax, the results from the per­protocol and complier 
average causal effect model analyses suggested an even 
greater advan tage to TURP (appendix p 6). All other 
prespecified sensitivity analyses agreed with the results 
of the primary analysis. We also saw no evidence that any 
prespecified subgroups altered these results (eg, age, 
lower urinary tract symptoms vs urinary retention, 
comorbidities, or prostate size; appendix p 7). While 
IPSS and Qmax levels could not be achieved at baseline 
for those diagnosed with urinary retention, the benefits 
of TURP were more apparent for participants with lower 
urinary tract symptoms (figure 2; appendix p 8). However, 
subgroup interaction tests at 12 months, although 
underpowered, could not consolidate this potential 
difference (p=0·888 for IPSS; p=0·189 for Qmax).
There were similar levels of perioperative and 
post­operative complications between the study groups 
(96 [47%] of 203 men in the TURP group vs 91 [45%] of 
204 men in the ThuVARP group had at least one 
post­operative complication), no cases of transurethral 
resection syndrome in either group, and no evidence of 
a difference in bleeding (tables 4, 5; appendix p 8). 
Mean hospital stay was 48 h for both groups and catheter 
requirement rates were low and similar between pro­
cedures. Although the proportion of men with 0 post­
void residual was almost equal in both groups (39 [23%] 
of 169 participants in the ThuVARP group versus 
39 [22%] of 176 participants in the TURP group), we 
observed evidence to suggest that post­void residual 
levels were higher in the ThuVARP group (table 5). 
Two men received a repeat TURP procedure for benign 
prostatic obstruction in the TURP group compared with 
three men in the ThuVARP group by 12­months post­
surgery (of those who received their original benign 
prostatic obstruction surgery). The median energy 
delivered for ThuVARP was 148 kJ (IQR 120–197; range 
of 20–987) based on 101 (66%) of 152 ThuVARP patients.
Questionnaire response rates at 12­months postsurgery 
varied across measures and were between 53% (IIEF; 
Score range (low 
to high severity)
ThuVARP (n=190) TURP (n=195) Adjusted difference* 
(95% CI)
p value*
IPSS—urinary symptoms†
IPSS storage subscale 0–15 3·82 (3·16) 3·54 (2·76) 0·36 (–0·25 to 0·98) 0·245
Frequency 0–5 1·28 (1·33) 1·25 (1·28) ·· ··
Urgency 0–5 0·90 (1·38) 0·84 (1·20) ·· ··
Nocturia 0–5 1·62 (1·13) 1·43 (1·10) ·· ··
IPSS voiding subscale 0–20 2·58 (3·78) 2·51 (3·40) 0·13 (–0·63 to 0·88) 0·740
Incomplete emptying 0–5 0·78 (1·16) 0·76 (1·03) ·· ··
Intermittency 0–5 0·63 (1·18) 0·68 (1·19) ·· ··
Weak stream 0–5 0·85 (1·36) 0·73 (1·16) ·· ··
Straining 0–5 0·33 (0·84) 0·42 (0·93) ·· ··
IPSS total score 0–35 6·29 (6·22) 6·03 (5·21) 0·43 (–0·78 to 1·64) 0·484
ICIQ-MLUTS—urinary symptoms‡
Voiding score 0–20 3·14 (3·40) 3·00 (3·07) 0·15 (–0·53 to 0·82) 0·666
Incontinence score 0–24 2·40 (2·65) 2·23 (2·37) 0·22 (–0·30 to 0·75) 0·406
Daytime frequency (>8 times) NA 20 (12%) 18 (10%) 1·20 (0·61 to 2·39) 0·597
Nocturia (>1 time per night) NA 72 (44%) 63 (37%) 1·47 (0·93 to 2·34) 0·102
ICIQ-MLUTS—sexual function§
Reduced or no erections NA 101 (70%) 113 (74%) 0·79 (0·47 to 1·31) 0·356
Reduced or no ejaculation NA 129 (93%) 136 (92%) 1·13 (0·47 to 2·71) 0·780
Painful ejaculation NA 8 (7%) 17 (12%) 0·55 (0·22 to 1·32) 0·179
Urinary symptoms affected sex life NA 74 (56%) 88 (61%) 0·81 (0·50 to 1·31) 0·399
International Index of Erectile Function—sexual function¶
Total score 25–5 14·18 (7·46) 15·14 (7·34) –0·95 (–2·95 to 1·05) 0·348
Data are n (%) or mean (SD), unless otherwise indicated. Based on exclusion of total withdrawals and numbers with indwelling catheters, the maximum number of potential 
responders was 190 for ThuVARP and 195 for TURP. ThuVARP=thulium laser transurethral vaporesection of the prostate. TURP=transurethral resection of the prostate. 
IPSS=International Prostate Symptom Score. ICIQ-MLUTS=International Consultation on Incontinence Questionnaire Male Lower Urinary Tract Symptoms Module. 
NA=not applicable. *ThuVARP compared with TURP, adjusted for centre and baseline diagnosis, using linear, logistic, or ordinal logistic regression; where data were skewed 
Mann-Whitney tests were used to ensure that conclusions drawn were appropriate. †Minimum numbers analysed were 151 patients for ThuVARP and 159 patients for TURP, 
with larger scores indicating more severe symptoms. ‡Minimum numbers analysed were 164 patients for ThuVARP and 172 patients for TURP, with larger scores indicating 
more severe symptoms. §Binary sexual patient reported outcomes were not adjusted for centre because of perfect prediction; minimum numbers analysed were 118 patients 
for ThuVARP and 139 patients for TURP. ¶Numbers analysed were 100 patients for ThuVARP and 118 patients for TURP; lower scores indicate more severe erectile 
dysfunction (5–7=severe, 8–11=moderate, 12–16=mild to moderate, 17–21=mild, and 22–25=none).
Table 6: Urinary symptoms and sexual function in all trial patients (presenting with lower urinary tract symptoms or urinary retention) at 12 months 
after surgery
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218 participants) and 83% (ICIQ satisfaction; 340 par­
ticipants), with over 75% of patients reporting on their 
urinary symptoms. Urinary symptoms were generally 
similar between the two study groups, with improvement 
from baseline apparent in patients with lower urinary 
tract symptoms (table 6; appendix pp 3, 9). However, 
TURP appeared to be slightly more effective in reducing 
the proportion of men reporting nocturia at 12 months, 
with 72 (44%) men getting up to urinate more than once 
per night in the ThuVARP group compared with 
63 (37%) in the TURP group. In an ordinal scale analysis 
(0–5 times per night) the p value for nocturia was 0·031.
Sexual dysfunction after surgery was very prevalent 
and generally similar between the two surgical groups 
at 12 months. A marginally lower level of painful 
ejaculation was observed in the ThuVARP group 
compared with the TURP group after surgery, but a 
difference between the groups was also apparent at 
baseline (tables 2, 6). At baseline, sexual dysfunction 
symptoms were common, with a high mean IIEF score, 
and 130 (70%) of 177 men had reduced or no erections. 
Overall there was little change in sexual symptoms after 
surgery in patients with lower urinary tract symptoms 
(appendix pp 4, 10). When comparing IIEF scores at 
base line and 12­months post­surgery in a post­hoc ana­
lysis (appendix p 10), 6 (24%) of 25 patients with lower 
urinary tract symptoms without sexual dysfunction 
reported at baseline had developed between mild and 
moderate symptoms after surgery. 22 (31%) of 70 patients 
with sexual dysfunction at baseline had increased sexual 
dysfunction after surgery. By contrast, 16 (23%) patients 
with sexual dysfunction at baseline had im proved sexual 
symptoms after surgery, with 32 (46%) of 70 patients’ 
symptoms remaining unchanged.
In general, there was no difference in quality of life at 
12­months postsurgery between the two study groups 
(table 7). 277 (82%) of 339 patients who answered the IPSS 
quality­of­life question at 12 months said they would be 
“mostly satisfied”, ”pleased”, or ”delighted” if they were to 
spend the rest of their lives with their urinary condition 
the way it is. Quality of life improved from baseline in 
patients with lower urinary tract symptoms (appendix 
p 3). Men in both study groups were satisfied with their 
treatment, with a mean satisfaction score of over 8·5 of 10, 
and 315 (93%) of 339 reported that they would definitely 
have the procedure again if required (table 7).
238 (70%) of 342 patients reported not knowing 
which operation they received. When asked “How did 
ThuVARP (n=190) TURP (n=195) Adjusted difference* 
(95% CI)
p value*
IPSS—quality of life†
IPSS quality of life 1·22 (1·67) 1·08 (1·46) 0·17 (–0·15 to 0·49) 0·294
ICIQ-LUTSqol—presence of limitations‡
Role limitations 40 (24%) 39 (23%) 1·11 (0·66 to 1·87) 0·690
Physical limitations 59 (36%) 55 (32%) 1·24 (0·77 to 2·00) 0·374
Social limitations 30 (18%) 33 (19%) 0·97 (0·56 to 1·69) 0·911
Personal relationships 76 (66%) 81 (63%) 1·18 (0·69 to 2·02) 0·555
Emotions 42 (26%) 52 (30%) 0·86 (0·52 to 1·42) 0·552
Sleep or energy 116 (72%) 129 (74%) 0·91 (0·55 to 1·50) 0·710
Severity measures 76 (47%) 97 (58%) 0·65 (0·41 to 1·03) 0·067
ICIQ-LUTSqol—urinary symptom effect on§
Getting embarrassed 23 (14%) 37 (21%) 0·61 (0·34 to 1·11) 0·108
Overall interference with everyday life 1·33 (2·39) 1·42 (2·27) –0·07 (–0·55 to 0·41) 0·778
ICIQ satisfaction¶
Overall, how satisfied were you with the treatment or 
procedure?
·· ·· –0·21 (–0·65 to 0·22) 0·338
On a scale of 0 (not) to 10 (very) 8·67 (2·42) 8·88 (1·92) ·· ··
If you were in the same situation again would you still 
have the same treatment or procedure?
·· ·· 1·90 (0·78 to 4·59) 0·156
Yes, definitely or probably 150 (91%) 165 (95%) ·· ··
Not sure 11 (7%) 5 (3%) ·· ··
No, definitely or probably not 4 (2%) 4 (2%) ·· ··
Data are mean (SD) or n (%), unless otherwise indicated. Based on exclusion of total withdrawals and numbers with indwelling catheters, the maximum number of potential 
responders was 190 for ThuVARP and 195 for TURP. ThuVARP=thulium laser transurethral vaporesection of the prostate. TURP=transurethral resection of the prostate. 
IPSS=International Prostate Symptom Score. ICIQ-LUTSqol=International Consultation on Incontinence Questionnaire Lower Urinary Tract Symptoms Quality of Life Module. 
*ThuVARP compared with TURP, adjusted for centre and baseline diagnosis, using linear, logistic, or ordinal logistic regression. †Numbers analysed were 164 patients for 
ThuVARP and 175 patients for TURP; higher scores indicate poorer quality of life. ‡Minimum numbers analysed were 115 patients for ThuVARP and 128 patients for TURP. 
§Minimum numbers analysed were 162 patients for ThuVARP and 173 for TURP; higher scores indicate poorer quality of life. ¶Numbers analysed were 163 patients for 
ThuVARP and 177 for TURP.
Table 7: Quality of life and satisfaction in all trial patients (presenting with lower urinary tract symptoms or urinary retention) 12 months after surgery
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you find out which type of surgery you had?”, 34 (10%) of 
342 men said they had found out accidentally during 
clinic or general practitioner (GP) visit or had asked the 
GP, consultant, or nurse.
Although exploratory in nature, routine histology 
review from prostate tissue removed during surgery 
revealed that a higher number of men were diagnosed 
with prostate cancer in the TURP group than in the 
ThuVARP group (appendix p 11). 25 (13%) of 193 men 
were diagnosed with prostate cancer in the TURP 
group compared with 10 (5%) of 193 in the ThuVARP 
group (odds ratio 0·35, 95% CI 0·16–0·75), probably 
because of the prostate weight available after resection, 
with the median resected weight 65% smaller after 
ThuVARP than after TURP (7 g compared with 20 g).
Discussion
In this study, ThuVARP was shown to be equivalent to 
TURP for patient­reported IPSS, but TURP was superior 
to ThuVARP for Qmax. However, the Qmax achieved by 
both procedures is considered clinically successful. Meta­
analyses have identified several randomised trials22–24 
comparing ThuVARP with TURP, although these were 
mostly done in Asia and on a smaller scale than this 
trial, and only one trial included patient blinding to an 
unspecified degree. In contrast to the results of this 
study, in one meta­analysis23 ThuVARP was significantly 
better in terms of both Qmax and IPSS, and ThuVARP 
and TURP were similar in the other two.22,24
We observed no difference between TURP and 
ThuVARP in terms of length of hospital stay, blood trans­
fusion rate, and drop in serum sodium after surgery in 
the UNBLOCS trial, unlike published meta­analyses 
in which ThuVARP was superior to TURP. The difference 
in hospital stay between previous studies and ours could 
be related to the previous studies being done in China, 
where most patients do not leave hospital until they can 
return to normal activities, thus increasing length of 
stay.8 In the UK, patients are encouraged to go home as 
soon as clinically appropriate, and patients are taught 
how to manage their catheters at home, until removal.
Overall, patient­reported outcomes were similar for 
TURP and ThuVARP for urinary and sexual symptoms, 
quality of life, and patient satisfaction, with no significant 
difference found between the study groups. However, 
there was a difference in nocturia between the groups, 
with an increased incidence at 12 months after surgery in 
the ThuVARP group, which warrants further investigation.
The effect of urinary symptoms on men’s sex life before 
surgery is substantial, with little improvement after 
surgery in patients with lower urinary tract symptoms 
overall. The occurrence of new onset erectile dysfunction 
is commonly reported as between 2% and 10% when 
patients are informed of surgical risks.25 When comparing 
IIEF scores by severity at baseline, surgery results in 
variable outcomes for individual patients, including 
some patients having improvements in their sexual 
function. The high level of sexual symptoms in patients 
at baseline supports the routine measurement of baseline 
sexual function in benign prostatic obstruction trials, 
and the variable outcome after surgery should be in­
cluded by clinicians in patient discussions.
The exploratory finding that the treatments differed in 
pathology diagnostic detection of prostate cancer might 
have been due to the reduced amount of tissue for 
histology from ThuVARP due to tissue vaporisation. The 
clinical significance of this finding is that a prostate 
cancer diagnosis might be missed because of the 
restricted histology available, although TURP is not part 
of the diagnostic pathway for prostate cancer.
A clinically important strength of UNBLOCS is the 
inclusion of patients with urinary retention (catheterised), 
who are usually excluded from benign prostatic ob struc­
tion surgical trials. To our knowledge, our study is 
unique in including patients with urinary retention 
and not restricting inclusion on prostate size. Therefore, 
published data on surgical outcomes for patients with 
urinary retention are scarce, with no comparative studies 
evaluating ThuVARP identified in a meta­analysis, and 
have been highlighted as a gap in the evidence base.26 
However, our results show that patients with urinary 
retention do as well with de­obstructing surgery as men 
with lower urinary tract symptoms, contrary to the belief 
that such surgery might not improve symptoms, possibly 
because of a higher prevalence of detrusor underactivity 
or acontractile bladder in men with urinary retention. As 
detrusor contractility cannot be measured in men with 
urinary retention, it is reassuring that the catheter­free 
rate was 98% at 3­months and 12­months postsurgery. 
This trial highlights the importance of including patients 
with urinary retention in all trials of new benign prostatic 
obstruction surgical techniques, as they comprise 50% of 
the patient population.
Another strength of our study was participant masking, 
with only 10% of patients reporting active unmasking, 
minimising bias. Masking is often considered unfeasible 
for surgical trials;22 however, it is particularly important 
with a patient­reported co­primary outcome (IPSS). Addi­
tionally, as all surgeons could do both ThuVARP and 
TURP, surgeons were also masked to the randomised 
allocation until the time of surgery. This strategy reduced 
bias in subjective assessment of symptoms, and we 
would recommend randomisation at the point of patient 
anaesthesia for masking in future surgical trials, where 
logistically possible.
Further strengths of this study were the large sample 
size compared with previous trials, the European setting, 
and successful recruitment despite the logistics of ran­
domisation at the point of surgery. The number of patients 
who withdrew was low and follow­up was high for a 
surgical trial with a patient­reported primary outcome.
The breadth of patient­reported outcomes has also 
produced novel findings, including data on incontinence 
in the ICIQ­MLUTS, which is absent from IPSS. 
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Inclusion of the more comprehensive ICIQ­MLUTSsex 
adds value to the generalisability of the IIEF and allows 
patients to express the effect of their urinary symptoms 
on sexual function without the assumption of an active 
sex life. As only 218 (53%) of 410 patients responded for 
IIEF, data should be treated with caution because of a 
potential risk of bias. However, this trial presents a 
comprehensive account of sexual function before and 
after benign prostatic obstruction surgery, identified as 
being poorly reported in trials of emerging procedures, 
in which prevalence rather than incidence data are 
reported because of a lack of preoperative data.27,28 
Inclusion of the ICIQ­Satisfaction questionnaire also 
provided insight into the patient experience of, and 
satisfaction with, surgery.
Limitations of the trial were the inevitable inability 
to collect some baseline data from the catheterised 
population with urinary retention, preventing adjust­
ment for baseline in the analysis. However, this 
limitation is outweighed by increased generalisability 
of the results. Before surgery, prostate volume was 
estimated by digital rectal examination rather than 
measured using transrectal ultrasound and prostate­
specific antigen testing and invasive urodynamics were 
not routinely done; however, this strategy mimics 
routine pragmatic clinical practice in the UK. The small 
number of men of non­white race included in the study 
is also a limitation.
The rate of conversion from ThuVARP to TURP 
during the trial could also be considered a limitation; 
however, this pragmatic trial reflects the real­life 
scenario should this laser technique be introduced into 
clinical practice. Additionally, per protocol and complier 
average causal effect sensitivity analyses accounted for 
crossover and had similar results to the main analysis. 
The size of the prostate also resulted in nine conver­
sions to TURP, which might reflect the lack of trial 
exclusion criteria for patients with large prostates. 
Future research into the comparative effectiveness of 
ThuVARP and TURP in large prostates would be 
useful.
A further potential limitation was the differential 
previous experience of the surgeons of TURP and 
ThuVARP, with trial surgeons having done over 
100 TURP procedures, but only between five and 
12 ThuVARP procedures.7 However, all surgeons were 
independently assessed before undertaking trial laser 
procedures and we have shown that ThuVARP has a 
short learning curve,7 with surgical skills similar to 
TURP. In comparing the conversion rates of ThuVARP 
to TURP during the trial, there was no evidence of a 
learning curve effect, with the rate of conversions 
actually increasing as surgeons conducted more cases.
In conclusion, both ThuVARP and TURP can be 
recommended as clinically effective procedures for 
relieving benign prostatic obstruction, however TURP 
achieved a superior maximum urinary flow rate (Qmax). 
The potential advantages of ThuVARP in reducing blood 
loss and shortening hospital stay were not observed in 
this study. Our results suggest that it is appropriate that 
new treatment alternatives continue to be compared with 
the current standard of TURP, as per NICE guidelines. 
Our trial results could be used to update the literature 
and urology guidelines, allowing patients to be more 
informed at the point of consent on the risks and benefits 
of such procedures, especially with regard to side­effects.
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